L. .. ,

M. De-compensation-de-l'immunophenotypage,

M. Sanguin and . .. Cmf-conventionnelle, , vol.86

D. .. ,

S. H. Swerdllow and N. L. Harris, WHO classification of tumours of haematopoietic and lymphoid tissues, 2008.

D. Selimoglu-buet, O. Wagner-ballon, V. Saada, V. Bardet, R. Itzykson et al., Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia, Blood. 4 juin, vol.125, issue.23, pp.3618-3644, 2015.

M. I. Saarni and J. W. Linman, Myelomonocytic leukemia: Disorderly proliferation of all marrow cells, Cancer. 1 mai, vol.27, issue.5, pp.1221-1251, 1971.
DOI : 10.1002/1097-0142(197105)27:5<1221::aid-cncr2820270530>3.0.co;2-p

URL : https://onlinelibrary.wiley.com/doi/pdf/10.1002/1097-0142%28197105%2927%3A5%3C1221%3A%3AAID-CNCR2820270530%3E3.0.CO%3B2-P

C. G. Geary, D. Catovsky, E. Wiltshaw, G. R. Milner, M. C. Scholes et al., Chronic Myelomonocytic Leukaemia, Br J Haematol. 1 juill, vol.30, issue.3, pp.289-302, 1975.

J. M. Bennett, D. Catovsky, M. T. Daniel, G. Flandrin, D. A. Galton et al., Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group, Br J Haematol. août, vol.33, issue.4, pp.451-459, 1976.

A. Orazi and U. Germing, The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features, Leukemia. juill, vol.22, issue.7, pp.1308-1327, 2008.

K. Takahashi, N. Pemmaraju, P. Strati, G. Nogueras-gonzalez, J. Ning et al., Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia, Blood, vol.17, issue.16, pp.2807-2811, 2013.
DOI : 10.1182/blood-2013-03-491399

URL : http://www.bloodjournal.org/content/122/16/2807.full.pdf

K. B. Kim, S. Faderl, C. S. Hwang, and F. R. Khuri, Chronic myelomonocytic leukaemia after platinum-based therapy for non-small cell lung cancer: case report and review of the literature, J Clin Pharm Ther. 1 août, vol.31, issue.4, pp.401-407, 2006.

E. Such, J. Cervera, D. Costa, F. Solé, T. Vallespí et al., Cytogenetic risk stratification in chronic myelomonocytic leukemia, Haematologica. mars, vol.96, issue.3, pp.375-83, 2011.
DOI : 10.3324/haematol.2010.030957

URL : http://www.haematologica.org/content/96/3/375.full.pdf

D. A. Sallman and E. Padron, Transformation of the Clinical Management of CMML Patients Through In-Depth Molecular Characterization, Clin Lymphoma Myeloma Leuk. juin, vol.15, pp.50-55, 2015.

M. M. Patnaik, E. Padron, R. R. Laborde, T. L. Lasho, C. M. Finke et al., Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes, Leukemia. 1 juill, vol.27, issue.7, pp.1504-1514, 2013.
DOI : 10.1038/leu.2013.88

URL : https://www.nature.com/articles/leu201388.pdf

M. M. Patnaik, T. L. Lasho, C. M. Finke, C. A. Hanson, J. M. Hodnefield et al., Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance, Am J Hematol. mars, vol.88, issue.3, pp.201-207, 2013.
DOI : 10.1002/ajh.23373

URL : https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.23373

A. M. Jankowska, H. Makishima, R. V. Tiu, H. Szpurka, Y. Huang et al., Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A, Blood, vol.118, issue.14, pp.3932-3973, 2011.
DOI : 10.1182/blood-2010-10-311019

URL : http://www.bloodjournal.org/content/118/14/3932.full.pdf

M. M. Patnaik, S. A. Parikh, C. A. Hanson, and A. Tefferi, Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review, Br J Haematol. mai, vol.165, issue.3, pp.273-86, 2014.
DOI : 10.1111/bjh.12756

URL : https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.12756

A. Tefferi, A. Levine, and R. L. , Role of TET2 and ASXL1 mutations in the pathogenesis of myeloproliferative neoplasms, Hematol Oncol Clin North Am, vol.26, issue.5, pp.1053-64, 2012.

C. Ricci, E. Fermo, S. Corti, M. Molteni, A. Faricciotti et al., RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant

, Clin Cancer Res Off J Am Assoc Cancer Res. 15 avr, vol.16, issue.8, pp.2246-56, 2010.

M. Kuo, D. Liang, C. Huang, Y. Shih, J. Wu et al., RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation, Leukemia. août, vol.23, issue.8, pp.1426-1457, 2009.
DOI : 10.1038/leu.2009.48

URL : https://www.nature.com/articles/leu200948.pdf

E. Padron, J. S. Painter, S. Kunigal, A. W. Mailloux, K. Mcgraw et al., GMCSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia, Blood. 20 juin, vol.121, issue.25, pp.5068-77, 2013.
DOI : 10.1182/blood-2012-10-460170

URL : http://www.bloodjournal.org/content/121/25/5068.full.pdf

, Blood Journal | Clonal architecture of chronic myelomonocytic leukemias

. Disponible,

E. Padron, S. Yoder, S. Kunigal, T. Mesa, J. K. Teer et al., ETV6 and signaling gene mutations are associated with secondary transformation of myelodysplastic syndromes to chronic myelomonocytic leukemia, Blood. 5 juin, vol.123, issue.23, pp.3675-3682, 2014.
DOI : 10.1182/blood-2014-03-562637

URL : http://www.bloodjournal.org/content/123/23/3675.full.pdf

L. Malcovati, E. Papaemmanuil, I. Ambaglio, C. Elena, A. Gallì et al., Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia, Blood. 28 août, vol.124, issue.9, pp.1513-1534, 2014.
DOI : 10.1182/blood-2014-03-560227

URL : http://www.bloodjournal.org/content/124/9/1513.full.pdf

, Leucémie myélomonocytaire chronique : diagnostic et thérapeutique-revmed

M. Cazzola, D. Porta, M. G. Malcovati, and L. , The genetic basis of myelodysplasia and its clinical relevance, Blood. 12 déc, vol.122, issue.25, pp.4021-4055, 2013.
DOI : 10.1182/blood-2013-09-381665

URL : http://www.bloodjournal.org/content/122/25/4021.full.pdf

P. Greenberg, C. Cox, M. M. Lebeau, P. Fenaux, P. Morel et al., International scoring system for evaluating prognosis in myelodysplastic syndromes, Blood. 15 mars, vol.89, issue.6, pp.2079-88, 1997.
DOI : 10.1182/blood-2012-03-420489

URL : http://www.bloodjournal.org/content/120/12/2454.full.pdf

F. Onida, H. M. Kantarjian, T. L. Smith, G. Ball, M. J. Keating et al., Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients, Blood. 1 févr, vol.99, issue.3, pp.840-849, 2002.

U. Germing, C. Strupp, M. Aivado, and N. Gattermann, New prognostic parameters for chronic myelomonocytic leukemia?, Blood. 15 juill, vol.100, issue.2, pp.731-734, 2002.
DOI : 10.1182/blood-2002-01-0330

URL : http://www.bloodjournal.org/content/100/2/731.full.pdf

U. Germing, C. Strupp, S. Knipp, A. Kuendgen, A. Giagounidis et al., Chronic myelomonocytic leukemia in the light of the WHO proposals, Haematologica. juill, vol.92, issue.7, pp.974-981, 2007.

E. Such, U. Germing, L. Malcovati, J. Cervera, A. Kuendgen et al., Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia, Blood. 11 avr, vol.121, issue.15, pp.3005-3020, 2013.

M. M. Patnaik, E. Padron, R. R. Laborde, T. L. Lasho, C. M. Finke et al., Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes, Leukemia. juill, vol.27, issue.7, pp.1504-1514, 2013.
DOI : 10.1038/leu.2013.88

URL : https://www.nature.com/articles/leu201388.pdf

M. M. Patnaik, R. Itzykson, T. L. Lasho, O. Kosmider, C. M. Finke et al., ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients, Leukemia. nov, vol.28, issue.11, pp.2206-2218, 2014.

R. Itzykson, O. Kosmider, A. Renneville, V. Gelsi-boyer, M. Meggendorfer et al., Prognostic score including gene mutations in chronic myelomonocytic leukemia, J Clin Oncol Off J Am Soc Clin Oncol. 1 juill, vol.31, pp.2428-2464, 2013.

. Consensusgfm2015,

M. M. Patnaik, S. A. Parikh, C. A. Hanson, and A. Tefferi, Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review, Br J Haematol. mai, vol.165, issue.3, pp.273-86, 2014.

P. Fenaux, G. J. Mufti, E. Hellstrom-lindberg, V. Santini, C. Finelli et al., Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study, Lancet Oncol. mars, vol.10, issue.3, pp.223-255, 2009.

L. Fianchi, M. Criscuolo, M. Breccia, L. Maurillo, F. Salvi et al., High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study, Leuk Lymphoma. mars, vol.54, issue.3, pp.658-61, 2013.

L. Adès, M. A. Sekeres, A. Wolfromm, M. L. Teichman, R. V. Tiu et al., Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine, Leuk Res. juin, vol.37, issue.6, pp.609-622, 2013.

R. Bejar, A. Lord, K. Stevenson, M. Bar-natan, A. Pérez-ladaga et al., TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients, Blood, vol.124, issue.17, pp.2705-2717, 2014.

L. Ziegler-heitbrock, P. Ancuta, S. Crowe, M. Dalod, V. Grau et al., Nomenclature of monocytes and dendritic cells in blood, Blood, vol.116, issue.16, pp.74-80, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00611173

F. Geissmann, S. Jung, and D. R. Littman, Blood monocytes consist of two principal subsets with distinct migratory properties, Immunity. juill, vol.19, issue.1, pp.71-82, 2003.

K. Allou, J. Vial, M. C. Béné, and F. Lacombe, The routine leukocyte differential flow cytometry HematoFlow TM method: A new flagging system for automatic validation

, Cytometry B Clin Cytom, vol.88, issue.6, pp.375-84, 2015.

M. Roussel, C. Benard, B. Ly-sunnaram, and T. Fest, Refining the white blood cell differential: The first flow cytometry routine application, Cytometry A. 1 juin, vol.77, issue.6, pp.552-63, 2010.

H. Kashiwagi, Y. Tomiyama, S. Honda, S. Kosugi, M. Shiraga et al., Molecular basis of CD36 deficiency. Evidence that a 478C->T substitution (proline90->serine) in CD36 cDNA accounts for CD36 deficiency, J Clin Invest. mars, vol.95, issue.3, pp.1040-1046, 1995.

C. Pastoret, , p.1

, CA) as part of the complete blood count (CBC) workflow. 2,3 The HF uses a cocktail of antibodies, including CD36 and CD16, to report a 5-part differential and cell subsets such as CD16 pos-and CD16 neg-monocyte. Here, we would like to report our experience in identifying CMML patients with the %CD16 neg Mo, on the basis of a regular CBC, We read with interest the article by Selimoglu-Buet and colleagues validating the fraction of CD16 neg-monocytes

, 08-2.33) for CMML and control groups, respectively. We found an optimal %CD16 neg Mo cutoff at 94% to discriminate CMML from control patients (sensitivity at 70.45%, specificity at 88.17% and area under the curve

D. Selimoglu-buet, O. Wagner-ballon, and V. Saada, Characteristic repartition of

M. Roussel, C. Benard, B. Ly-sunnaram, and T. Fest, Refining the white blood cell differential: the first flow cytometry routine application, Cytometry A, vol.77, issue.6, pp.552-563, 2010.

M. Roussel, B. H. Davis, T. Fest, and B. L. Wood, Toward a reference method for leukocyte differential counts in blood: Comparison of three flow cytometric candidate methods, Cytometry A

A. Cottard, O. Wagner-ballon, L. Priol, and J. , Improvement of the leukocyte differential performed by flow cytometry using the advanced 2.0 version of the CytoDiff CXP software
URL : https://hal.archives-ouvertes.fr/hal-01060858

, Cytometry A, vol.85, issue.8, pp.653-657, 2014.